Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 446 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glioma, Sarcomatous Clear all
Completed Phase 2 Interventional

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

NCT00014573
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 25, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional Results available

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

NCT00436436
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, temozolomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 25, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00387894
View directory record Official record
Conditions
Adult Brain Tumors
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Michael Prados
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 25, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional

Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

NCT00238277
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, adjuvant therapy, chemotherapy, radiation therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

NCT02658981
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
Interventions
Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137
Biological · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

NCT00005081
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

NCT00036972
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cintredekin besudotox, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

NCT03452930
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Radiation Therapy, Tinostamustine
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 25, 2026, 6:07 AM EDT
Terminated Phase 1 Interventional

Bortezomib in Treating Patients With Recurrent Glioma

NCT00006773
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00895180
View directory record Official record
Conditions
Adult Glioblastoma Multiforme
Interventions
olaratumab, ramucirumab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT03174197
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Atezolizumab, Radiation Therapy, Temozolomide
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Primary Brain Tumors

NCT00002824
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gene therapy, chemotherapy, ganciclovir, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

NCT00004024
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, muromonab-CD3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

NCT00354068
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
imatinib mesylate, temozolomide, pharmacological study
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

NCT03360708
View directory record Official record
Conditions
Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00362921
View directory record Official record
Conditions
Recurrent Adult Brain Tumor
Interventions
Gliadel wafers in combination with O6-benzylguanine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

NCT01119599
View directory record Official record
Conditions
Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Primary Melanocytic Lesion of Meninges, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma
Interventions
3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Therapeutic Conventional Surgery
Radiation · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Sep 25, 2026, 6:07 AM EDT
Terminated Phase 1 Interventional Results available

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma

NCT02664363
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
EGFRvIII CAR T cells
Biological
Lead sponsor
Daniel Landi
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 25, 2026, 6:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT01189240
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

NCT00074243
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
CC-8490
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 25, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT00014443
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
thalidomide, topotecan hydrochloride
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors

NCT01032200
View directory record Official record
Conditions
Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
Interventions
Armodafinil, placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 25, 2026, 6:07 AM EDT
Completed Phase 1Phase 2 Interventional

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

NCT00006093
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cilengitide
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 25, 2026, 6:07 AM EDT